Healthcare provider profile · identity verified

Phillip Scott Williams, DO

Family Practice · GROVE, OK · NPI 1245522549

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	418	128
Lisinopril	Lisinopril	284	87
Rosuvastatin Calcium	Rosuvastatin Calcium	275	82
Albuterol Sulfate Hfa	Albuterol Sulfate	250	76
Levothyroxine Sodium	Levothyroxine Sodium	241	62
Gabapentin	Gabapentin	226	72
Metformin Hcl	Metformin Hcl	209	53
Amlodipine Besylate	Amlodipine Besylate	197	59
Pantoprazole Sodium	Pantoprazole Sodium	183	58
Losartan Potassium	Losartan Potassium	173	52
Montelukast Sodium	Montelukast Sodium	159	37
Pregabalin	Pregabalin	159	29
Sertraline Hcl	Sertraline Hcl	148	37
Tamsulosin Hcl	Tamsulosin Hcl	146	48
Omeprazole	Omeprazole	140	34
Metoprolol Succinate	Metoprolol Succinate	137	41
Metoprolol Tartrate	Metoprolol Tartrate	137	35
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	121	17
Glimepiride	Glimepiride	101	28
Escitalopram Oxalate	Escitalopram Oxalate	98	24
Furosemide	Furosemide	97	34
Hydrochlorothiazide	Hydrochlorothiazide	92	23
Potassium Chloride	Potassium Chloride	88	27
Fluticasone Propionate	Fluticasone Propionate	87	23
Famotidine	Famotidine	82	20
Atenolol	Atenolol	80	16
Ozempic	Semaglutide	77	23
Trazodone Hcl	Trazodone Hcl	76	25
Diclofenac Sodium	Diclofenac Sodium	73	22
Duloxetine Hcl	Duloxetine Hcl	72	14
Meloxicam	Meloxicam	72	17
Baclofen	Baclofen	70	18
Clopidogrel	Clopidogrel Bisulfate	70	22
Carvedilol	Carvedilol	69	24
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	66	12
Pravastatin Sodium	Pravastatin Sodium	66	22
Allopurinol	Allopurinol	64	17
Lovastatin	Lovastatin	62	19
Ondansetron Odt	Ondansetron	60	20
Citalopram Hbr	Citalopram Hydrobromide	59	15
Pioglitazone Hcl	Pioglitazone Hcl	59	13
Prednisone	Prednisone	59	50
Trulicity	Dulaglutide	57	12
Ezetimibe	Ezetimibe	56	19
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	55	12
Fenofibrate	Fenofibrate	54	15
Doxycycline Hyclate	Doxycycline Hyclate	52	39
Mirtazapine	Mirtazapine	51	14
Enalapril Maleate	Enalapril Maleate	49	11
Nabumetone	Nabumetone	49	20
Celecoxib	Celecoxib	46	13
Finasteride	Finasteride	42	15
Fluoxetine Hcl	Fluoxetine Hcl	42	suppressed
Jardiance	Empagliflozin	42	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	14
Eliquis	Apixaban	40	13
Buspirone Hcl	Buspirone Hcl	38	suppressed
Ventolin Hfa	Albuterol Sulfate	38	11
Metformin Hcl Er	Metformin Hcl	36	12
Alendronate Sodium	Alendronate Sodium	35	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	35	suppressed
Januvia	Sitagliptin Phosphate	34	11
Simvastatin	Simvastatin	34	12
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	31	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	31	suppressed
Meclizine Hcl	Meclizine Hcl	30	14
Breo Ellipta	Fluticasone/Vilanterol	29	suppressed
Bupropion Xl	Bupropion Hcl	29	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Symbicort	Budesonide/Formoterol Fumarate	29	suppressed
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	26	suppressed
Estradiol	Estradiol	26	suppressed
Cephalexin	Cephalexin	25	22
Chlorthalidone	Chlorthalidone	25	suppressed
Indapamide	Indapamide	25	suppressed
Torsemide	Torsemide	25	suppressed
Spironolactone	Spironolactone	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	24	16
Warfarin Sodium	Warfarin Sodium	24	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	23	suppressed
Spiriva Respimat	Tiotropium Bromide	23	suppressed
Tradjenta	Linagliptin	20	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Clonidine	Clonidine	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Ondansetron Hcl	Ondansetron Hcl	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	16
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Glipizide Er	Glipizide	16	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Farxiga	Dapagliflozin Propanediol	15	suppressed
Promethazine Hcl	Promethazine Hcl	15	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	suppressed
Ramipril	Ramipril	14	suppressed
Scopolamine	Scopolamine	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Metronidazole	Metronidazole	13	suppressed
Nystatin	Nystatin	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Etodolac	Etodolac	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Propranolol Hcl	Propranolol Hcl	12	suppressed
Sodium Chloride	0.9 % Sodium Chloride	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Varenicline Tartrate	Varenicline Tartrate	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Wegovy	Semaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error